Here's something that doesn't happen every day: pharmaceutical stocks are suddenly the cool kids at the Wall Street party. November has marked what Tema ETFs founder and CEO Maurits Pot calls "a striking inflection point few had expected" for a sector that's spent years being thoroughly ignored.

In an exclusive conversation this week, Pot laid out why pharma is entering what he believes is a genuine structural transformation. And no, this isn't about hyped-up tech valuations masquerading as innovation. Healthcare stocks remain cheap by historical standards, AI is delivering measurable impact, and the performance rally is just getting started.

The Numbers Behind November's Healthcare Surge

While everyone's been arguing about whether AI is a bubble by pointing at sky-high tech multiples, healthcare has quietly been putting up numbers that make even hot AI trades look modest. The Health Care Select Sector SPDR Fund (XLV) is up 10% month-to-date. The iShares Biotechnology ETF (IBB) has gained 8%. But here's where it gets interesting: the Tema Oncology ETF (CANC) has absolutely ripped, rallying 45% year-to-date and climbing more than 15% in November alone.

That's not a typo. Cancer-focused stocks are outperforming the broader market by a wide margin.

"What often happens is the need precedes the performance, and performance precedes the flows," Pot explained. "We're on the cusp of seeing that inflection."

The Perfect Storm: Patent Cliffs Meet Rising Demand

So what's driving this sudden surge? According to Pot, it's the collision of three powerful forces. First, chronic disease isn't getting better—it's getting worse. Healthcare demand has never been stronger globally. Second, major pharmaceutical companies are staring down what the industry calls patent cliffs, where their blockbuster drugs lose exclusivity and revenue drops off a cliff. Third, artificial intelligence is making drug discovery faster and cheaper than ever before.

"We live in a world where chronic disease is getting worse, not better. Pharma demand has never been stronger," Pot said.

The patent cliff problem is particularly acute. When a major drug loses patent protection, generic competition can obliterate 90% of its revenue practically overnight. Big pharma needs to replace those revenue streams, and they need to do it fast. That creates what Pot describes as a powerful demand-and-supply dynamic: exploding global demand for treatment innovation colliding with drugmakers' desperate need for new products.

When Regulatory Fog Lifts, Deals Start Flowing

After years of uncertainty around drug pricing policies, vaccine mandates, and political involvement in healthcare, the regulatory picture is finally clearing. That matters more than you might think.

"With regulatory clarity coming in, people realize three things," Pot said. "The need for healthcare hasn't changed—if anything, it's gone up. Healthcare valuations are very cheap relative to history. And historically, a lot of the returns in healthcare come from big companies buying small companies."

The result has been a wave of acquisitions. "You're now seeing the biggest oncology deal in five years, the biggest cardiometabolic deal in five years," Pot noted. When big pharma gets nervous about their pipelines and regulatory uncertainty fades, they start writing checks. Lots of them.

Who's Winning The Pharma Race?

Pot highlighted Eli Lilly & Co. (LLY) as the standout performer, praising the company's execution across obesity, neurology, and oncology. "I think Eli Lilly has been ahead of the curve in many things," he said. Though he also noted that some of the most interesting innovation is happening at smaller, independent companies flying below the radar.

When it comes to the heavyweight battle between Eli Lilly and Novo Nordisk A/S (NVO) in diabetes and obesity treatment, Pot didn't mince words. "Lilly has just had much better execution," he said. "Novo Nordisk was too bloated, too slow."

What AI Is Actually Doing In Drug Discovery

Let's clear up what AI is and isn't doing in pharmaceutical research right now. According to Pot, AI is dramatically speeding up the R&D cycle and making it substantially cheaper. That's huge because it means more margin available to reinvest in further discoveries.

"Drug discovery cycles are getting shorter. Costs are coming down. That means there's more margin to reinvest in further discoveries," Pot explained.

But here's the reality check: AI isn't independently discovering new drug molecules yet. "Right now, AI is enabling or making drug discovery more efficient—but it's not actually discovering molecules yet," Pot clarified.

The real promise lies in what's still developing. One significant benefit could be in handling the complex regulatory requirements of FDA submission processes. "A lot of that work can be simplified now with AI," Pot said. This matters most when new health crises emerge suddenly. "AI may be able to come up with drug solutions faster than the conventional discovery cycle."

The Cancer Moonshot: Chronic, Not Deadly

Here's where things get genuinely exciting. Pot described three major developments that could fundamentally redefine cancer treatment over the next decade. First, gene editing may make certain cancers treatable at the DNA level. Second, cancer could shift from being a death sentence to a manageable chronic condition, like diabetes. Third, a cancer vaccine may actually become reality.

The companies leading this charge, according to Pot, are Merck & Co. (MRK) and Moderna Inc. (MRNA).

"If you were to ask me what the moonshot innovation of this decade is in oncology, it's either a cancer vaccine or it's gene editing," he said.

Think about what that means for a moment. We could be approaching a world where getting diagnosed with certain cancers doesn't mean planning your funeral—it means managing a chronic condition with regular treatment. Or getting a vaccine that prevents it entirely. That's not science fiction anymore; it's where the serious research dollars are flowing.

After years of languishing performance, pharma stocks are having their moment. Whether that moment turns into a sustained rally depends on whether these AI-accelerated discoveries can actually deliver the breakthroughs everyone's betting on. But with regulatory clarity improving, M&A accelerating, and some of the smartest scientists in the world armed with AI tools, the odds are looking better than they have in years.